LFY inhibitors refer to a class of chemical compounds that interfere with the activity of LEAFY (LFY), a transcription factor critical in the regulation of floral development in plants. LEAFY plays an essential role in the transition from vegetative growth to flowering, acting as a master regulator in the genetic network that dictates the formation of floral meristems and the differentiation of flower structures. Inhibition of LFY can lead to delays or alterations in flower development by blocking the expression of downstream target genes that are responsible for initiating floral organ identity. LFY inhibitors, therefore, serve as tools to modulate this key genetic pathway, providing insights into the intricate processes controlling plant reproductive development. These inhibitors target the LFY protein's function by either binding to the transcription factor itself or disrupting its interaction with other key proteins involved in floral gene regulation.
The use of LFY inhibitors has been of particular interest in studies investigating the molecular mechanisms of flowering and the regulation of floral organ development. By interfering with LEAFY's activity, researchers can examine the phenotypic effects on various plant species, allowing for a deeper understanding of the genetic and molecular frameworks that guide floral architecture. Such compounds can also be employed to probe the regulatory networks and feedback loops in which LFY operates, thus revealing how plants integrate environmental and endogenous signals to fine-tune the timing of flowering. Additionally, LFY inhibitors may help explore the evolutionary significance of the transcription factor across different plant lineages, offering clues to how flowering plants diversified in form and function through molecular adaptations.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D inhibits LFY by binding to DNA and preventing RNA synthesis, thus disrupting the transcriptional regulation of LFY. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits LFY by blocking protein synthesis, leading to the downregulation of LFY expression and activity. | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
Rifampicin inhibits LFY by targeting bacterial RNA polymerase, indirectly affecting LFY expression in bacteria. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin inhibits LFY indirectly by inducing DNA damage and activating apoptotic pathways, resulting in decreased LFY expression. | ||||||
Bleomycin | 11056-06-7 | sc-507293 | 5 mg | $275.00 | 5 | |
Bleomycin inhibits LFY by causing DNA strand breaks, which triggers apoptotic pathways and reduces LFY expression. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $78.00 $260.00 | 18 | |
Hydroxyurea inhibits LFY by interfering with DNA synthesis, leading to cell cycle arrest and downregulation of LFY expression. | ||||||
Topotecan | 123948-87-8 | sc-338718 | 100 mg | $582.00 | ||
Topotecan inhibits LFY by inhibiting topoisomerase I, causing DNA damage and subsequently reducing LFY expression. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Fluorouracil inhibits LFY indirectly by disrupting DNA synthesis and promoting apoptosis, resulting in decreased LFY expression. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate inhibits LFY by blocking dihydrofolate reductase, leading to impaired DNA synthesis and downregulation of LFY expression. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin inhibits LFY by inhibiting topoisomerase I, leading to DNA damage and downregulation of LFY expression. | ||||||